维康药业
Search documents
中药板块12月29日跌0.9%,*ST长药领跌,主力资金净流出6.89亿元
Zheng Xing Xing Ye Ri Bao· 2025-12-29 09:06
Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.9% on December 29, with *ST Changyao leading the drop. The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1]. Group 1: Stock Performance - The following stocks in the traditional Chinese medicine sector showed notable performance: - WoHua Pharmaceutical (002107) closed at 6.33, up 2.43% with a trading volume of 106,100 shares and a transaction value of 65.58 million yuan [1]. - Tianmu Pharmaceutical (600671) closed at 17.39, up 1.81% with a trading volume of 22,600 shares and a transaction value of 39.17 million yuan [1]. - Weikang Pharmaceutical (300878) closed at 25.75, up 0.66% with a trading volume of 20,500 shares and a transaction value of 53.04 million yuan [1]. - Tongrentang (600085) closed at 32.46, up 0.65% with a trading volume of 168,300 shares and a transaction value of 221 million yuan [1]. - Yunnan Baiyao (000538) closed at 56.69, down 0.02% with a trading volume of 61,100 shares and a transaction value of 346 million yuan [1]. Group 2: Capital Flow - The traditional Chinese medicine sector saw a net outflow of 689 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2]. - Notable capital flows for specific stocks include: - Tongrentang (600085) had a net inflow of 28.03 million yuan from institutional investors, but a net outflow of 19.15 million yuan from retail investors [3]. - Wanbangde (002082) experienced a net inflow of 12.49 million yuan from institutional investors, with a net outflow of 9.44 million yuan from retail investors [3]. - Ma Yinglong (600993) had a net inflow of 5.11 million yuan from institutional investors, while retail investors saw a net inflow of 3.19 million yuan [3].
中药板块12月19日涨0.69%,维康药业领涨,主力资金净流出3857.06万元
Zheng Xing Xing Ye Ri Bao· 2025-12-19 09:01
从资金流向上来看,当日中药板块主力资金净流出3857.06万元,游资资金净流出9028.32万元,散户资 金净流入1.29亿元。中药板块个股资金流向见下表: 证券之星消息,12月19日中药板块较上一交易日上涨0.69%,维康药业领涨。当日上证指数报收于 3890.45,上涨0.36%。深证成指报收于13140.22,上涨0.66%。中药板块个股涨跌见下表: 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。 ...
266只股中线走稳 站上半年线
Zheng Quan Shi Bao Wang· 2025-12-19 08:16
Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 3890.45 points, above the half-year line, reflecting a gain of 0.36% and a total trading volume of 1.748742 trillion yuan [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3890.45 points, above the half-year line, with a gain of 0.36% [1] - Total trading volume in the A-share market reached 1.748742 trillion yuan [1] Group 2: Stocks Breaking Half-Year Line - A total of 266 A-shares have surpassed the half-year line, indicating strong market interest [1] - Notable stocks with significant deviation rates include: - GQY Vision (10.23%) - Hongwei Technology (9.84%) - Zhongwang Fabric (8.75%) [1] Group 3: Detailed Stock Data - GQY Vision: Today's price increased by 11.23% with a turnover rate of 13.78%, latest price at 7.23 yuan [1] - Hongwei Technology: Today's price increased by 12.30% with a turnover rate of 17.12%, latest price at 27.49 yuan [1] - Zhongwang Fabric: Today's price increased by 9.98% with a turnover rate of 1.78%, latest price at 25.78 yuan [1]
A股收评 | 沪指3连阳 指数全线反弹!背后原因浮现
智通财经网· 2025-12-19 07:12
今日市场全线反弹,沪指录得3连阳。盘面上,题材继续轮动,大消费方向持续走强,海南自贸区、可 控核聚变、地产等板块涨幅居前。市场全天成交约1.7万亿,较上个交易日小幅放量,两市上涨个股超 4400只。 对于今日指数全线上涨的原因,分析人士表示,美国11月非农部门就业人数、美国11月消费者价格指数 (CPI)等数据相继公布,日本央行今天上午宣布将目标利率提高25个基点至0.75%,符合市场预期。随着 一系列"靴子"落地,A股短期面临的外部不确定性消散,市场关注点开始转向A股自身内部。 盘面上看,大消费方向再度拉升,零售、乳业、犒赏经济等细分概念领涨,免税概念龙头股中国中免盘 中一度触及涨停,收盘暴涨超8%;海南板块午后涨幅扩大,海汽集团、海南发展、海南海药等多股涨 停;房地产板块震荡反弹,中天服务3连板,三湘印象、华联控股等领涨;核聚变概念大涨,王子新 材、四创电子等多股涨停;AI医疗概念活跃,维康药业、新诺威领涨;汽车产业链震荡上行,浙江世 宝4连板、路畅科技涨停;下跌方面,半导体、贵金属、银行等板块领跌。 展望后市,兴业证券认为,近期重磅会议奠定的国内外积极的政策组合,创造了有利于风险资产演绎的 良好环境,跨 ...
【盘中播报】249只个股突破半年线
Zheng Quan Shi Bao Wang· 2025-12-19 06:48
Group 1 - The Shanghai Composite Index closed at 3887.81 points, above the six-month moving average, with a gain of 0.30% [1] - The total trading volume of A-shares reached 1,390.087 billion yuan [1] - A total of 249 A-shares have surpassed the six-month moving average, with notable stocks including GQY Vision, Hongwei Technology, and Zhongwang Fabric, showing significant deviation rates of 12.05%, 9.88%, and 8.75% respectively [1] Group 2 - GQY Vision (300076) had a daily increase of 13.08% with a turnover rate of 10.52%, and its latest price was 7.35 yuan, showing a deviation rate of 12.05% [1] - Hongwei Technology (688711) increased by 12.34% with a turnover rate of 15.68%, latest price at 27.50 yuan, and a deviation rate of 9.88% [1] - Zhongwang Fabric (605003) rose by 9.98% with a turnover rate of 1.76%, latest price at 25.78 yuan, and a deviation rate of 8.75% [1]
创新药概念震荡反弹,益方生物涨超10%
Mei Ri Jing Ji Xin Wen· 2025-12-19 02:19
(文章来源:每日经济新闻) 每经AI快讯,12月19日,创新药概念震荡反弹,益方生物涨超10%,新诺威、维康药业、亚虹医药、阳 光诺和、悦康药业跟涨。 ...
维康药业:关于公司药品生产许可证变更的公告
Zheng Quan Ri Bao· 2025-12-15 11:04
证券日报网讯 12月15日晚间,维康药业发布公告称,公司于近日取得浙江省药品监督管理局换发的 《药品生产许可证》,换发后的《药品生产许可证》有效期至2030年12月11日。 (文章来源:证券日报) ...
维康药业:公司药品生产许可证变更
Ge Long Hui· 2025-12-15 08:56
格隆汇12月15日丨维康药业(300878.SZ)公布,近日取得浙江省药品监督管理局换发的《药品生产许可 证》,换发后的《药品生产许可证》有效期至2030年12月11日。本次换发《药品生产许可证》是基于原 许可证即将到期,新证的取得确保了公司的正常生产经营,对公司业绩无重大影响。 ...
维康药业(300878.SZ):公司药品生产许可证变更
Ge Long Hui A P P· 2025-12-15 08:56
格隆汇12月15日丨维康药业(维权)(300878.SZ)公布,近日取得浙江省药品监督管理局换发的《药品 生产许可证》,换发后的《药品生产许可证》有效期至2030年12月11日。本次换发《药品生产许可证》 是基于原许可证即将到期,新证的取得确保了公司的正常生产经营,对公司业绩无重大影响。 ...
维康药业(300878) - 关于公司药品生产许可证变更的公告
2025-12-15 08:42
证券代码:300878 证券简称:维康药业 公告编号:2025-051 浙江维康药业股份有限公司 关于公司药品生产许可证变更的公告 质量负责人:纪晓燕 发证机关:浙江省药品监督管理局 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司(以下简称"公司")于近日取得浙江省药品监 督管理局换发的《药品生产许可证》,换发后的《药品生产许可证》有效期至 2030 年 12 月 11 日,主要相关信息如下: 一、《药品生产许可证》基本情况 企业名称:浙江维康药业股份有限公司 注册地址:浙江省丽水经济开发区遂松路 2 号 社会信用代码:913311007047968289 法定代表人:刘洋 企业负责人:刘洋 有效期至:2030 年 12 月 11 日 许可证编码:浙 20000144 分类码:AhzyCh 生产地址和生产范围:浙江省丽水经济开发区遂松路 2 号:中药饮片〔含毒 性饮片、含直接口服饮片〕、丸剂(滴丸)、滴剂(胶囊型)(仅限注册申报使 用)、片剂、胶囊剂、软胶囊剂、颗粒剂*** 二、对公司的影响及风险提示 本次换发《药品生产许可证》是基于 ...